Medipal Holdings Corp ADR (MAHLY) Fair Value & Analysis
Healthcare · US · Market cap $3.2B · ISIN US58502T1079
What is Medipal Holdings Corp ADR really worth?
Medipal Holdings Corp ADR
MAHLY · US
A solid business, trading 42% below our fair value of $31.50.
Strengths
Risks
For context
Fair value as of: Aug 28, 2026
From 23 valuation models · updated 8 days ago
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price is below even our cautious bear case ($24.20). The market is more pessimistic than our downside scenario.
- Solid quality (63/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.
How to read this chart
60‑month range $11.05 – $19.30 · fair‑value band $24.20 – $38.27 · the $18.30 price screens below the $31.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 28, 2026.
Analysis
Medipal Holdings Corp ADR (MAHLY) currently trades at $18.30, while our model-based Fair Value estimate is $31.50, implying the stock looks roughly 41.9% undervalued today. The Quality Score stands at 63/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of $33.02 per share, and 20 of the 23 models we run sit above the $18.30 price. Bear case: the Asset-Based group reads lowest at $13.93, and 3 of the 23 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Medipal Holdings Corp ADR generated revenue of $3.8T at a net margin of 1.1%. Revenue grew 4.8% year over year. It earns a return on equity of 6.8%. The balance sheet holds a net cash position of $290B. Fundamentals as of Aug 28, 2026
Our scenario range runs from $24.20 (bear case) to $38.27 (bull case); at $18.30, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 5% below its 52-week high and 17% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 72%, MAHLY screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 23 models by family
Widest divergence: DCF Models ($33.02) versus Asset-Based ($13.93). Highest evidence: FCF DCF (82).
Notify me when MAHLY reaches fair value
Put MAHLY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 60
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprising medical equipment and medical materials, and clinical diagnostic reagents for use from the pre-symptomatic stage; handles PMS services on contract for …
Full company description
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprising medical equipment and medical materials, and clinical diagnostic reagents for use from the pre-symptomatic stage; handles PMS services on contract for manufacturers; and invests in orphan drugs and other products. The company is also involved in the wholesale of cosmetics, daily necessities, and OTC pharmaceuticals; and animal health products for companion animals; and food processing raw materials for agriculture, fisheries, and livestock. In addition, it engages in the contract-based epidemiological studies, clinical studies, etc.; creation of a computerized medical supply database and master product databases for medical facilities; life and non-life insurance agency business; cleaning management; management and operation of distribution centers; commissioned delivery and worker dispatch business; planning, management, administration, and product and service development for the class A health dispensing pharmacies service brand; and distributes specialty pharmaceuticals. Further, the company is involved in contract logistics services; information provision services; health insurance claims review, medical coding dispatch, outsourcing and remote education; and creation of a medical supply database and master product databases for medical facilities. It serves hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fish producers, and processed food manufacturers. The company was formerly known as Mediceo Paltac Holdings Co., Ltd. and changed its name to Medipal Holdings Corporation in October 2009. Medipal Holdings Corporation was founded in 1898 and is headquartered in Tokyo, Japan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Medipal Holdings Corp ADR reported revenue of $4.0T in FY2026 versus $3.3T in FY2022, a compound +5.3%/yr. Reported net income was $45.1B in FY2026, compounding +11.3%/yr from FY2022.
of which total revenue +2.6 % · buybacks/dilution +0.9 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch MAHLY: get an alert when its fair value changes →
Peer Group
Medical Distribution · 78 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $906.77 | $819.31 | −10% |
| Cencora, Inc COR | $330.97 | $211.07 | −36% |
| Cardinal Health, Inc CAH | $234.55 | $141.77 | −40% |
| Henry Schein, Inc HSIC | $88.46 | $71.70 | −19% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.37 | ¥33.96 | +107% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Galenica AG GALE | CHF 80.85 | CHF 61.79 | −24% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.03 | ¥28.65 | +36% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| Asker Healthcare Group ASKER | kr 74.40 | kr 28.26 | −62% |
Compare Medipal Holdings Corp ADR with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Medipal Holdings Corp ADR (MAHLY) overvalued or undervalued?
What is the fair value of MAHLY?
What is the quality score of MAHLY?
What is the revenue of Medipal Holdings Corp ADR (MAHLY)?
What is the net profit margin of MAHLY?
Does Medipal Holdings Corp ADR pay a dividend?
Watch Medipal Holdings Corp ADR in the live analysis
One click puts Medipal Holdings Corp ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.